Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 37 of 37 publications.
Skip to main content
Paret K, Chaiyakunapruk N, Ronquest N, Pearson I. Introduction to best practices for country adaptations of economic models - virtual. Presented at the 2025 Virtual ISPOR Short Course Program; March 26, 2025. Previously presented at the 2024 Virtual ISPOR Short Course Program.
Paret K, Chaiyakunapruk N, Ronquest N, Pearson I. Introduction to best practices for country adaptations of economic models - virtual. Presented at the 2024 Virtual ISPOR Short Course Program; October 2, 2024.
Tahami Monfared AA, Phan NTN, Pearson I, Mauskopf J, Cho M, Zhang Q, Hampel H. A systematic review of clinical practice guidelines for Alzheimer's disease and strategies for future advancements. Neurol Ther. 2023 Aug;12(4):1257-84. doi: 10.1007/s40120-023-00504-6
Spelman T, Herring WL, Zhang Y, Tempest M, Pearson I, Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand’Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in the United Kingdom. Pharmacoeconomics. 2022 Mar;40(3):323-39. doi: 10.1007/s40273-021-01106-6.
Spentzouris G, Bilitou A, Manga N, McCrink L, Pearson I, Mitchell S, Moss E, Rothwell B. Systematic literature review of cost and data sources for economic evaluations in hypercholesterolaemia and mixed dyslipidaemia from a UK perspective. Poster presented at the Virtual ISPOR Europe 2021; November 30, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.
Lunan M, Hartley L, Pearson I, Doyle S. Targeted literature review of the burden of illness in late-stage Duchenne Muscular Dystrophy (DMD). Poster presented at the Virtual ISPOR Europe 2021; November 3, 2021. [abstract] Value Health. 2021 Dec; 24(12):S2.
Noon K, Costello J, Krieger T, Rothwell B, Pearson I. Utility weight considerations in NICE immune checkpoint inhibitor oncology appraisals. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).
Krieger T, Pearson I, Bell J, Doherty J, Robbins P. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. Diagn Pathol. 2020 Jan 30;15(1):6. doi: 10.1186/s13000-020-0927-9
Pearson I, Stevenson A, Krieger T, Ling C. What is the role of the company evidence submission in National Institute for Health and Care Excellence (NICE) multiple technology appraisals? Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).
Igarashi A, Kusel J, Pearson I, Ronquest N. Do innovative technologies require innovative appraisal techniques? - case studies from recent HTAs in the UK, US and Japan. Presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark.
Knight C, Pearson I. Economic modelling considerations for rare diseases. Presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark.
Robbins PB, Krieger T, Pearson I, Bell J, Doherty J. Use of TMB and PD-L1 to predict outcomes of checkpoint inhibitor treatment. Poster presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium; March 1, 2019. San Francisco, CA.
Heyes A, McBride D, Pearson I, Copley-Merriman C. HTA and reimbursement considerations for rare diseases in European markets: what are the implications for manufacturers? Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Mordin M, Fernandez M, Pearson I, Copley-Merriman K, McBride D. Similarities and differences in European HTA evidence requirements: one for all or one for none? Presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD.
Pearson I, Rothwell B, Olaye A, Knight C. Economic modeling considerations for rare diseases. Value Health. 2018 May;21(5):515-24.
Herring WL, Zhang Y, Pearson I, Tempest M, Freudensprung U, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase registry: comparing natalizumab to fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis (RRMS) in Scotland. Poster presented at the 2018 American Academy of Neurology Annual Meeting; April 22, 2018. Los Angeles, CA. Previously presented at the 7th Joint ECTRIMS-ACTRIMS Meeting.
Masaquel C, Hurley D, Barnett B, Krieger T, Pearson I, Copley-Merriman C, Kaye JA, Moy B. Clinical and economic burden of HER2-positive breast cancer recurrence in the US: a literature review. Poster presented at the 2017 San Antonio Breast Cancer Symposium; December 7, 2017. San Antonio, TX.
Herring W, Zhang Y, Pearson I, Tempest M, Freudensprung U, Acosta C, Hyde R, Spelman T, Butzkueven H. A cost-effectiveness analysis using real-world data from the MSBase registry: comparing natalizumab to fingolimod in patients with inadequate response to disease modifying therapies in relapsing-remitting multiple sclerosis in Scotland. Poster presented at the 7th Joint ECTRIMS-ACTRIMS Meeting; October 26, 2017. Paris, France.
Herring W, Pearson I, Purser M, Nakhaipour HR, Haiderali A, Wolowacz S, Jayasundara K. Cost effectiveness of ofatumumab plus chlorambucil in first-line chronic lymphocytic leukaemia in Canada. Pharmacoeconomics. 2016 Jan;34(1):77-90. doi: 10.1007/s40273-01509332-5
Pearson IV, Hawe E, Zuluaga S, Scuito S, Wolowacz S, Haiderali A. Cost-effectiveness of ofatumumab plus chlorambucil in first-line chronic lymphocytic leukemia in the United Kingdom. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Wolowacz S, Pearson I, Shannon P, Chubb B, Gundgaard J, Davies M, Briggs A. Development and validation of a cost-utility model for Type 1 diabetes mellitus. Diabet Med. 2015 Aug;32(8):1023-35. doi: 10.1111/dme.12663
Wolowacz SE, Hawe E, Pearson IV. Use of external data to guide long-term survival extrapolations of trial data for chronic lymphocytic leukemia. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam.
Herring WL, Pearson IV, Purser MF, Nakhaipour HR, Haiderali A, Wolowacz SE, Jayasundara K. Cost-effectiveness of ofatumumab plus chlorambucil in first line chronic lymphocytic leukemia in Canada. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):PA633.
Pearson I, Rycroft C, Irving A, Ainsworth C, Wittrup-Jensen K. A systematic literature review of utility weights in wet age-related macular degeneration. J Med Econ. 2013 Nov;16(11):1307-16.
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Helbert M, Pang F, Alvarez-Reyes M, Pearson IV, Wolowacz S, Diwakar L. A cost-effectiveness comparison of icatibant and c1-esterase inhibitor concentrate for the symptomatic treatment of acute attacks of types i and ii hereditary angioedema in the UK setting. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 13, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A513.
Pearson IV, Wolowacz SE, Irving AH, Brockbank JA, Chubb B, Gundgaard J, Briggs A, Davies M. A systematic review of recent data describing the risk of complications in type 1 diabetes mellitus patients. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 9, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A496-7.
Wolowacz SE, Pearson IV, Roskell NS, Shannon PR, Chubb B, Gundgaard J. Development and validation of a cost-utility model for Type 1 diabetes mellitus. Presented at the Mount Hood Six Challenge; June 7, 2012.
Rycroft CE, Pearson IV, Khan S, Heyes AE. A tale of four countries: comparing reimbursement submission requirements in Ireland, England, Wales, and Scotland. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. [abstract] Value Health. 2010 Nov; 13(7):A418-9.
Pearson IV, Johnson KI. A cost minimization analysis of epoetin zeta for the treatment of anemia associated with chronic kidney disease. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. [abstract] Value Health. 2008 May; 11(3):A304.
Pearson IV, Page MD, van Spanning RJM, Ferguson SJ. A mutant of paracoccus denitrificans with disrupted genes coding for cytochrome c550 and pseudoazurin establishes these two proteins as the in vivo electron donors to cytochrome cd1 nitrite reductase. J Bacteriol. 2003 Nov 1;185(21):6308-15.